(Q84485392)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

main subject

myelodysplastic syndrome

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

D Wolff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

T Gromke

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

R Trenschel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

A H Elmaagacli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

U Pichlmeier

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

C Junghanss

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

M Freund

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

D W Beelen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

J Casper

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

28 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

502-509

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20581886%20AND%20SRC:MED&resulttype=core&format=json

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Treosulfan as an effective second-line therapy in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Cellular and clinical pharmacology of fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Allogeneic stem cell transplantation for myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.153

7 January 2021